WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research…
Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA
In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…
Intensive Patient Education May Not Be Helpful for Acute Low Back Pain
Education with recommended first-line care may not improve pain outcomes in patients with acute low back pain. When comparing patients who received education with those who received professional consultation without information or advice, researchers found patient education was no more effective than placebo at reducing depression or incidence of chronic low back pain…
Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices
WASHINGTON (Reuters)—U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. Democrats have been critical of efforts by the Trump administration to bring down drug prices after President Donald Trump promised to do so during his campaign and since being…
New York City Launches $100 Million Universal Health Insurance Program
NEW YORK (Reuters)—New York City has launched a $100 million health insurance program to cover 600,000 uninsured residents, including those unable to afford coverage and those living in the United States illegally, Mayor Bill de Blasio said on Tuesday. De Blasio, now in his second term as mayor of the country’s most populous city, has…
Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
BOSTON (Reuters)—The former chief executive of Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker’s CEO in 2015, pleaded guilty in federal court in Boston to…
A Step Further: Results from the 1st ACR/ARHP Annual Meeting Walking Challenge
With more than 152,000 taken steps in four days, top honors in the first-ever ACR/ARHP Annual Meeting Walking Challenge go to Mark Phelan, MD…
Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE
Patients who develop neuropsychiatric symptoms of SLE have a small nucleotide polymorphism (SNP) in an intron in a Ca++ ion channel gene that influences some, but not all, events regulated by Ca++. The SNP appears to influence activation induced apoptosis rates and cytokine production, specifically IL-4, in a disease- and genotype-specific manner…
FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…
Why I Chose to Be Part of RheumPAC
As physicians, we play an important role in the well-being of patients and serve as advocates to ensure our patient receives adequate healthcare services. Unfortunately, many of the policy decisions that govern our medical practices are made by bureaucrats with inadequate input from physicians. Certain constraints placed on the way we should practice medicine have…
- « Previous Page
- 1
- …
- 272
- 273
- 274
- 275
- 276
- …
- 798
- Next Page »